Expression Pattern and Prognostic Value of Key Regulators for m6A RNA Modification in Hepatocellular Carcinoma

As the most prevalent type of mRNA modification in mammals, N6-methyladenosine (m6A) is involved in various biological processes. Accumulating studies have indicated that the deregulation of m6A RNA modification is linked to cancer and other diseases. However, its implications in hepatocellular carc...

Full description

Bibliographic Details
Main Authors: Lele Zhang, Yiting Qiao, Jiacheng Huang, Dalong Wan, Lin Zhou, Shengzhang Lin, Shusen Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Medicine
Subjects:
m6A
Online Access:https://www.frontiersin.org/article/10.3389/fmed.2020.00556/full
id doaj-2462e38d81ea424a9367759df186a61d
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Yiting Qiao
Yiting Qiao
Yiting Qiao
Yiting Qiao
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Dalong Wan
Lin Zhou
Lin Zhou
Lin Zhou
Lin Zhou
Shengzhang Lin
Shengzhang Lin
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
spellingShingle Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Yiting Qiao
Yiting Qiao
Yiting Qiao
Yiting Qiao
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Dalong Wan
Lin Zhou
Lin Zhou
Lin Zhou
Lin Zhou
Shengzhang Lin
Shengzhang Lin
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
Expression Pattern and Prognostic Value of Key Regulators for m6A RNA Modification in Hepatocellular Carcinoma
Frontiers in Medicine
m6A
hepatocellular carcinoma
bioinformatics
prognostic signature
nomogram
author_facet Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Lele Zhang
Yiting Qiao
Yiting Qiao
Yiting Qiao
Yiting Qiao
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Jiacheng Huang
Dalong Wan
Lin Zhou
Lin Zhou
Lin Zhou
Lin Zhou
Shengzhang Lin
Shengzhang Lin
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
Shusen Zheng
author_sort Lele Zhang
title Expression Pattern and Prognostic Value of Key Regulators for m6A RNA Modification in Hepatocellular Carcinoma
title_short Expression Pattern and Prognostic Value of Key Regulators for m6A RNA Modification in Hepatocellular Carcinoma
title_full Expression Pattern and Prognostic Value of Key Regulators for m6A RNA Modification in Hepatocellular Carcinoma
title_fullStr Expression Pattern and Prognostic Value of Key Regulators for m6A RNA Modification in Hepatocellular Carcinoma
title_full_unstemmed Expression Pattern and Prognostic Value of Key Regulators for m6A RNA Modification in Hepatocellular Carcinoma
title_sort expression pattern and prognostic value of key regulators for m6a rna modification in hepatocellular carcinoma
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2020-09-01
description As the most prevalent type of mRNA modification in mammals, N6-methyladenosine (m6A) is involved in various biological processes. Accumulating studies have indicated that the deregulation of m6A RNA modification is linked to cancer and other diseases. However, its implications in hepatocellular carcinoma (HCC) remain poorly characterized. Herein, we sought to investigate the expression pattern of 13 key regulators for m6A RNA modification and to evaluate their prognostic value in HCC. First, we systematically analyzed data from The Cancer Genome Atlas (TCGA) database pertaining to patient clinical information and mRNA gene expression data. We found that 11 out of 13 key regulators for m6A RNA modification showed significantly higher expression levels in HCC. Subsequently, we identified two subgroups (clusters 1 and 2) via consensus clustering based on the expression of 13 m6A RNA methylation regulators. Cluster 2 had a worse prognosis and was also significantly correlated with higher histological grade and pathological stage when compared with cluster 1. Moreover, cluster 2 was remarkedly enriched for cancer-related pathways. We further constructed a robust risk signature of five regulators for m6A RNA modification. Further analysis indicated that this risk signature could be an independent prognostic factor for HCC, and the prognostic relevance of this five-gene risk signature was successfully validated using the Gene Expression Omnibus (GEO) dataset. Finally, we established a novel prognostic nomogram on the basis of age, gender, histological grade, pathological stage, and risk score to precisely predict the prognosis of patients with HCC. In summary, we herein uncovered the vital role of regulators for m6A RNA modification in HCC and developed a risk signature as a promising prognostic marker in HCC patients.
topic m6A
hepatocellular carcinoma
bioinformatics
prognostic signature
nomogram
url https://www.frontiersin.org/article/10.3389/fmed.2020.00556/full
work_keys_str_mv AT lelezhang expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT lelezhang expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT lelezhang expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT lelezhang expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT lelezhang expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT yitingqiao expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT yitingqiao expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT yitingqiao expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT yitingqiao expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT jiachenghuang expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT jiachenghuang expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT jiachenghuang expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT jiachenghuang expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT jiachenghuang expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT dalongwan expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT linzhou expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT linzhou expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT linzhou expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT linzhou expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT shengzhanglin expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT shengzhanglin expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT shusenzheng expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT shusenzheng expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT shusenzheng expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT shusenzheng expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
AT shusenzheng expressionpatternandprognosticvalueofkeyregulatorsform6arnamodificationinhepatocellularcarcinoma
_version_ 1724606373562417152
spelling doaj-2462e38d81ea424a9367759df186a61d2020-11-25T03:23:25ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2020-09-01710.3389/fmed.2020.00556581736Expression Pattern and Prognostic Value of Key Regulators for m6A RNA Modification in Hepatocellular CarcinomaLele Zhang0Lele Zhang1Lele Zhang2Lele Zhang3Lele Zhang4Yiting Qiao5Yiting Qiao6Yiting Qiao7Yiting Qiao8Jiacheng Huang9Jiacheng Huang10Jiacheng Huang11Jiacheng Huang12Jiacheng Huang13Dalong Wan14Lin Zhou15Lin Zhou16Lin Zhou17Lin Zhou18Shengzhang Lin19Shengzhang Lin20Shusen Zheng21Shusen Zheng22Shusen Zheng23Shusen Zheng24Shusen Zheng25The First Affiliated Hospital, Zhejiang University School of Medicine, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Hangzhou, ChinaSchool of Medicine, Zhejiang University, Hangzhou, ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Hangzhou, ChinaThe First Affiliated Hospital, Zhejiang University School of Medicine, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Hangzhou, ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Hangzhou, ChinaThe First Affiliated Hospital, Zhejiang University School of Medicine, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Hangzhou, ChinaSchool of Medicine, Zhejiang University, Hangzhou, ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Hangzhou, ChinaThe First Affiliated Hospital, Zhejiang University School of Medicine, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Hangzhou, ChinaThe First Affiliated Hospital, Zhejiang University School of Medicine, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Hangzhou, ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Hangzhou, ChinaSchool of Medicine, Zhejiang University, Hangzhou, ChinaShulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, ChinaThe First Affiliated Hospital, Zhejiang University School of Medicine, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Hangzhou, ChinaNHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, ChinaKey Laboratory of the Diagnosis and Treatment of Organ Transplantation, Research Unit of Collaborative Diagnosis and Treatment for Hepatobiliary and Pancreatic Cancer, Chinese Academy of Medical Sciences (2019RU019), Hangzhou, ChinaKey Laboratory of Organ Transplantation, Hangzhou, ChinaShulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, ChinaAs the most prevalent type of mRNA modification in mammals, N6-methyladenosine (m6A) is involved in various biological processes. Accumulating studies have indicated that the deregulation of m6A RNA modification is linked to cancer and other diseases. However, its implications in hepatocellular carcinoma (HCC) remain poorly characterized. Herein, we sought to investigate the expression pattern of 13 key regulators for m6A RNA modification and to evaluate their prognostic value in HCC. First, we systematically analyzed data from The Cancer Genome Atlas (TCGA) database pertaining to patient clinical information and mRNA gene expression data. We found that 11 out of 13 key regulators for m6A RNA modification showed significantly higher expression levels in HCC. Subsequently, we identified two subgroups (clusters 1 and 2) via consensus clustering based on the expression of 13 m6A RNA methylation regulators. Cluster 2 had a worse prognosis and was also significantly correlated with higher histological grade and pathological stage when compared with cluster 1. Moreover, cluster 2 was remarkedly enriched for cancer-related pathways. We further constructed a robust risk signature of five regulators for m6A RNA modification. Further analysis indicated that this risk signature could be an independent prognostic factor for HCC, and the prognostic relevance of this five-gene risk signature was successfully validated using the Gene Expression Omnibus (GEO) dataset. Finally, we established a novel prognostic nomogram on the basis of age, gender, histological grade, pathological stage, and risk score to precisely predict the prognosis of patients with HCC. In summary, we herein uncovered the vital role of regulators for m6A RNA modification in HCC and developed a risk signature as a promising prognostic marker in HCC patients.https://www.frontiersin.org/article/10.3389/fmed.2020.00556/fullm6Ahepatocellular carcinomabioinformaticsprognostic signaturenomogram